Infant RSV shot | Lilly Alzheimer's drug | J&J sues Medicare

VIEW IN BROWSER | SUBSCRIBE FRI, JUL 21, 2023 EDITOR'S NOTE Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Families will finally have an option to protect their newborns against respiratory syncytial virus, the leading cause of hospitalization among infants.    The FDA approved AstraZeneca and Sanofi's Beyfortus this week, a monoclonal antibody that is administered as a single shot before or during an infant's first RSV season.   RSV overwhelmed children's hospitals last fall, triggering calls for the Biden administration to declare a public health emergency. Beyfortus, if widely adopted, promises to substantially reduce the burden of RSV on families and the health system.   The U.S. may soon have a second drug in its arsenal to help slow Alzheimer's disease. Eli Lilly said this week that it expects the FDA to make a decision on donanemab by the end of the year.    And Johnson & Johnson this week joined the pharmaceutical industry's campaign to take down Medicare's new powers to slash drug prices. J&J is the third drugmaker to directly challenge the Biden administration in court.   The U.S. Chamber of Commerce and PhRMA, the pharmaceutical industry's lobby group, have also filed lawsuits against the drug negotiations.    Feel free to send any tips, suggestions, story ideas and data to me at spencer.kimball@nbcuni.com. Spencer Kimball | Health Reporter @spencekimball   Spencer Kimball | Health Reporter @spencekimball   FDA approves AstraZeneca, Sanofi shot that protects infants and toddlers against RSV RSV is the leading cause of hospitalization among children less than a year old, according to scientists. - Spencer Kimball Johnson & Johnson sues Biden administration over Medicare drug price negotiations Merck, Bristol Myers Squibb, the U.S. Chamber of Commerce and PhRMA filed separate lawsuits against the provision last month. - Annika Kim Constantino Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the year Eli Lilly is racing to market donanemab for Alzheimer's after Eisai and Biogen's drug for the disease, Leqembi, won FDA approval this month. - Annika Kim Constantino Johnson & Johnson beats on earnings, hikes full-year guidance as medtech sales surge The results come amid investor anxiety over the thousands of lawsuits claiming that J&J's talc-based baby powder and other products caused cancer. - Annika Kim Constantino Kenvue shares fall even as J&J spinoff beats estimates in first quarterly earnings since IPO J&J still owns a 90% stake in Kenvue, meaning it can generally control the direction of the consumer health spinoff's business for the time being. - Annika Kim Constantino Nearly 3 million people cut from Medicaid coverage even though many might still be eligible About 75% of the 2.7 million people who have lost Medicaid were booted from the program because they did not complete the process to renew their coverage. - Spencer Kimball Medicare proposes removing limit on PET scans used to help diagnose Alzheimer's disease Medicare's proposal to cover PET scans for Alzheimer's would make it easier for patients to access new drugs like Leqembi. - Spencer Kimball JOIN US REGISTER REGISTER CONTRIBUTORS Bertha Coombs @berthacoombs Annika Kim Constantino @annikakimc   Bertha Coombs @berthacoombs Annika Kim Constantino @annikakimc   Unsubscribe Digital Products Manage Newsletters Feedback Terms of Service Privacy Policy Join the CNBC Panel © 2023 CNBC LLC. All rights reserved. A property of NBCUniversal.   900 Sylvan Avenue, Englewood Cliffs, NJ 07632   Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes and Market Data and Analysis.   Data also provided by THOMSON REUTERS

If you believe this has been sent to you in error, please safely unsubscribe.